Eli Heyman1,2, Eli Lahat1,2, Noa Levin1, Orna Epstein1, Mirit Lazinger1, Matitiahu Berkovitch2,3, Revital Gandelman-Marton2,4. 1. Department of Pediatric Neurology, Assaf Harofeh Medical Center, Zerifin, Israel. 2. Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel. 3. Clinical Pharmacology Unit, Assaf Harofeh Medical Center, Zerifin, Israel. 4. Electroencephalography Laboratory, Assaf Harofeh Medical Center, Zerifin, Israel.
Abstract
AIM: There are few reports on the tolerability and efficacy of perampanel, a new antiepileptic drug with a novel mechanism of action, in children and adolescents. We aimed to describe our experience with perampanel add-on and mono-therapy in children with refractory epilepsy. METHOD: Computerized medical records of children treated with perampanel in the paediatric neurology clinic from December 2012 to October 2015 were reviewed. RESULTS: Twenty-four children treated with perampanel (15 females, 9 males) aged 1 year 6 months to 17 years (mean 10y, standard deviation [SD] 4y 5mo) were identified. Adverse events were more common in children aged 12 years or older (89%) compared to younger children (53%), and were mainly behavioural. Ten (42%) children had 50 per cent or higher seizure reduction, two (8%) children had 33 per cent seizure reduction, and seizures were less severe in one (4%) child. Perampanel was discontinued in 13 (54%) children mostly due to adverse events. The mean duration of follow-up in the remaining 11 children was 8.1 months (SD 5.2) (range 1.3-17mo). INTERPRETATION: Perampanel is associated with a relatively high rate of behavioural adverse events mostly in adolescents with refractory epilepsy.
AIM: There are few reports on the tolerability and efficacy of perampanel, a new antiepileptic drug with a novel mechanism of action, in children and adolescents. We aimed to describe our experience with perampanel add-on and mono-therapy in children with refractory epilepsy. METHOD: Computerized medical records of children treated with perampanel in the paediatric neurology clinic from December 2012 to October 2015 were reviewed. RESULTS: Twenty-four children treated with perampanel (15 females, 9 males) aged 1 year 6 months to 17 years (mean 10y, standard deviation [SD] 4y 5mo) were identified. Adverse events were more common in children aged 12 years or older (89%) compared to younger children (53%), and were mainly behavioural. Ten (42%) children had 50 per cent or higher seizure reduction, two (8%) children had 33 per cent seizure reduction, and seizures were less severe in one (4%) child. Perampanel was discontinued in 13 (54%) children mostly due to adverse events. The mean duration of follow-up in the remaining 11 children was 8.1 months (SD 5.2) (range 1.3-17mo). INTERPRETATION:Perampanel is associated with a relatively high rate of behavioural adverse events mostly in adolescents with refractory epilepsy.
Authors: Song Ee Youn; Se Hee Kim; Ara Ko; Sun Ho Lee; Young Mock Lee; Hoon Chul Kang; Joon Soo Lee; Heung Dong Kim Journal: J Clin Neurol Date: 2018-07 Impact factor: 3.077